Neuroprotection and Functional Recovery Associated with Decreased Microglial Activation Following Selective Activation of mGluR2/3 Receptors in a Rodent Model of Parkinson's Disease

Clinical trials have demonstrated positive proof of efficacy of dual metabotropic glutamate receptor 2/3 (mGluR2/3) agonists in both anxiety and schizophrenia. Importantly, evidence suggests that these drugs may also be neuroprotective against glutamate excitotoxicity, implicated in the pathogenesis...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Hugh, Paur, Helen, Vernon, Anthony C., Zabarsky, Virginia, Datla, Krishna P., Croucher, Martin J., Dexter, David T.
Formato: Texto
Lenguaje:English
Publicado: SAGE-Hindawi Access to Research 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2951138/
https://www.ncbi.nlm.nih.gov/pubmed/20948891
http://dx.doi.org/10.4061/2010/190450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2951138/
https://www.ncbi.nlm.nih.gov/pubmed/20948891
http://dx.doi.org/10.4061/2010/190450

Ejemplares similares